Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542

Japan

Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EP Vantage PD-1 / PD-L1 Combination Therapies 2017

Immuno-oncology combination trials triple since 2015

Keytruda now partner of choice

EP Vantage PD-1/PD-L1 Combination Therapies 2017 EP Vantage PD-1/PD-L1 Combination Therapies 2017 EP Vantage PD-1/PD-L1 Combination Therapies 2017

Download Report

This report examines the explosion in the number of clinical trials using anti-PD-1 and anti-PD-L1 antibodies combined with other therapeutic approaches. When we published our first report in November 2015 there were 215 studies, but as of April 2017 there were 765.

There is little to suggest a slowdown in this field, given the speed with which immuno-oncology combination studies have proliferated and the blockbuster potential of the anti-PD-1/PD-L1 class.

Key Highlights:

  • There are now 268 combo trials involving Keytruda and 242 with Opdivo, of which 86 combine Opdivo with Yervoy. Keytruda’s dominance comes as the drug continues to impress in clinical trials
  • The number of studies combining anti-PD-1/PD-L1s with chemotherapy have surged, potentially spurred by Roche’s efforts with Tecentriq
  • The most popular indication for combinations is lung cancer, which makes up the biggest single market (16%), followed by melanoma and sarcoma (13%), which has so far showed the best efficacy for PD-1/PD-L1s
  • IO-IO combos also represent a significant part of the analysis. Keytruda, Opdivo and Tecentriq are in 56, 54 and 32 IO-IO combo studies respectively

Press Release


Confirm your details on form below to download this report